Article citationsMore>>

C. M. Wright, J. E. Larsen, M. L. Colosimo, J. J. Barr, L. Chen, R. E. McLachlan, I. A. Yang, R. V. Bowman and K. M. Fong, “Genetic Association Study of CYP1A1 Polymorphisms Identifies Risk Haplotypes in Nonsmall Cell Lung Cancer,” European Respiratory Journal, Vol. 35, No. 1, 2010, pp. 152-159. doi:10.1080/07357900902849657

has been cited by the following article:

• TITLE: Increased Risk of Acute Myeloid Leukemia in Patients with CYP1A1 Polymorphisms

  AUTHORS: Luís Arthur Flores Pelloso, Ismael Dale Cotrim Guerreiro da Silva, Naiara Côrrea Nogueira de Souza, Mihoko Yamamoto, Maria de Lourdes L. Ferrari Chauffaille

  KEYWORDS: Acute Myeloid Leukemia; Karyotype; GSTM1; GSTT1; CYP1A1; Gene Polymorphisms; Genetic PolymorPhisms; Biomarker

  JOURNAL NAME: Journal of Cancer Therapy, Vol.4 No.5, June 28, 2013

  ABSTRACT: Acute Myeloid Leukemia (AML) is a group of genetically diverse hematopoietic malignancies arising from cell progenitors developing in the myeloid pathway or from primitive stem cells. Genetic susceptibility of AML may account for an increased risk of AML due to partial metabolism of or biocativation of carcinogens. Chemical compounds are metabolized by a two-tiered phase detoxifying system. Polymorphisms in these pathways may lead to DNA damage and development of AML. We determined the frequencies of carcinogen metabolism gene polymorphisms (CYP1A1, del{GSTM1} and del{GSTT1}) in a case control-study based on polymorphism analysis. Fifty-eight consecutively AML patients (median age 62 years) and 174 sex and age-matched control group were assessed by a PCR-RFLP assay. There were 51 de novo and 7 secondary AML. CYP1A1*2A and CYP1A1*2C polymorphisms were more frequent in CG than AML p 0.001 and in contrast, CYP1A1*3 and CYP1A1*4 were more frequent in AML than CG p 0.001. There were no differences in del{GSTM1} neither del{GSTT1} between AML and CG (p = 0.999 and p = 0.539). Odds ratio for AML in patients harboring CYP1A1*3 was 2.36 (95% CI 1.2 - 4.5), 2.38 for CYP1A1*4 (95% CI 0.8 - 6.8). Adjusted OR was 2.63 for CYP1A1*3 (95% CI 1.4 - 5.1) and 2.66 for CYP1A1*4 (95% CI 0.9 - 7.8). In the multivariate analysis CYP1A1*3 polymorphism was a risk factor for AML with an OR for 3.99 (95%CI 1.9 - 8.6). To the best of our knowledge this is the first study to show that CYP1A1*3 heterozygous genotypes increase the risk of AML. Our data support that inherited absence of this carcinogen detoxification pathway may be an important determinant of AML.